VINH PHUC PHARMACEUTICAL JOINT - STOCK COMPANY

vinphaco.vn

With motto "for public health"​, the medical ethics of the physician in who produce as well as in business to defend the interest people the client Everlasting Lucky materia medica joint stock company (have VINPHACO business name) always exaltted is motto what VINPHACO always tend.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AEGLE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA FOR AGLE-102 FOR PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

Aegle Therapeutics | October 06, 2020

news image

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerat...

Read More

RESEARCH

TURTLETREE LAUNCHES NEW RESEARCH AND DEVELOPMENT FACILITY IN GREATER SACRAMENTO

TurtleTree | October 04, 2021

news image

TurtleTree has officially opened its new R&D facility in California's state capital. Located in West Sacramento, this 24,000-square-foot building will house a world-class research hub showcasing the company's extensive array of innovations and cell-based technologies. Representing a milestone in TurtleTree's US-based expansion plans, the research facility will spur the development of precision fermentation technology currently used to produce valuable milk in...

Read More

LEXOGEN AND ONRAMP BIOINFORMATICS PARTNER TO PROVIDE DIFFERENTIAL GENE EXPRESSION DATA ANALYSIS AND INTERPRETATION FOR QUANTSEQ 3' MRNA-SEQ USERS

Lexogen | June 17, 2020

news image

Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowle...

Read More

INDUSTRIAL IMPACT

INVENTORS OF BIOLAYER INTERFEROMETRY TECHNOLOGY LAUNCH A NEXT GEN PLATFORM AND NOVEL BIOSENSORS

Gator Bio | September 15, 2021

news image

Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific applica...

Read More
news image

AEGLE THERAPEUTICS RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM THE FDA FOR AGLE-102 FOR PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

Aegle Therapeutics | October 06, 2020

Aegle Therapeutics Corporation, a first-in-class biotechnology company committed to delivering cell-free therapy to patients affected by severe dermatological conditions, today announced that the FDA has granted Rare Pediatric Disease (RPD) Designation to AGLE-102™ for the treatment of dystrophic epidermolysis bullosa (DEB), a skin blistering disorder. AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerat...

Read More
news image

RESEARCH

TURTLETREE LAUNCHES NEW RESEARCH AND DEVELOPMENT FACILITY IN GREATER SACRAMENTO

TurtleTree | October 04, 2021

TurtleTree has officially opened its new R&D facility in California's state capital. Located in West Sacramento, this 24,000-square-foot building will house a world-class research hub showcasing the company's extensive array of innovations and cell-based technologies. Representing a milestone in TurtleTree's US-based expansion plans, the research facility will spur the development of precision fermentation technology currently used to produce valuable milk in...

Read More
news image

LEXOGEN AND ONRAMP BIOINFORMATICS PARTNER TO PROVIDE DIFFERENTIAL GENE EXPRESSION DATA ANALYSIS AND INTERPRETATION FOR QUANTSEQ 3' MRNA-SEQ USERS

Lexogen | June 17, 2020

Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND™, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowle...

Read More
news image

INDUSTRIAL IMPACT

INVENTORS OF BIOLAYER INTERFEROMETRY TECHNOLOGY LAUNCH A NEXT GEN PLATFORM AND NOVEL BIOSENSORS

Gator Bio | September 15, 2021

Gator Bio, Inc. announced today the launch of the GatorPlus, a next generation biolayer interferometry (BLI) instrument and two new biosensor products, Gator™ Flex SA Kit and Gator™ AAVX probe. The GatorPlus adds to the currently available GatorPrime instrument; and the new Gator™ Flex SA Kit and Gator™ AAVX probe expand the off the shelf biosensor portfolio to 14 products for the North America market. Gator Bio also offers on demand custom biosensors for specific applica...

Read More